Essa Pharma Stock Investor Sentiment

EPIX Stock  USD 1.69  0.03  1.74%   
Slightly above 83 percent of ESSA Pharma's investors are selling. The analysis of the overall investor sentiment regarding ESSA Pharma suggests that a fairly large number of traders are terrified. ESSA Pharma's investing sentiment can be driven by a variety of factors including economic data, ESSA Pharma's earnings reports, geopolitical events, and overall market trends.

Comfort Level 17

 Terrified

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use ESSA Pharma's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward ESSA Pharma.

ESSA Historical Sentiment

Although ESSA Pharma's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding ESSA, such as negative comments on social media and news outlets, may cause fear in the market and push ESSA Pharma's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of ESSA.
  

ESSA Pharma Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards ESSA Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

ESSA Pharma Historical Investor Sentiment

Investor biases related to ESSA Pharma's public news can be used to forecast risks associated with an investment in ESSA. The trend in average sentiment can be used to explain how an investor holding ESSA can time the market purely based on public headlines and social activities around ESSA Pharma. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
ESSA Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for ESSA Pharma and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average ESSA Pharma news discussions. The higher the estimate score, the more favorable the investor's outlook on ESSA Pharma.
over three months ago at thelincolnianonline.com         
ESSA Pharma Rating Lowered to Market Perform at Oppenheimer
news
over three months ago at thelincolnianonline.com         
ESSA Pharma Stock Rating Lowered by Jefferies Financial Group
news
over three months ago at investing.com         
Bb biotech ag sells Essa Pharma shares for 12 million
Investing News at Macroaxis
over three months ago at finance.yahoo.com         
ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trials
Yahoo News
over three months ago at benzinga.com         
Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination ...
benzinga news
over three months ago at seekingalpha.com         
ESSA Pharma tanks after terminating trial for its prostate cancer treatment
seekingalpha News
over three months ago at benzinga.com         
Disposition of 1879583 shares by Biotech Growth N V of ESSA Pharma at 1.513 subject to Rule 16b-3
benzinga news
over three months ago at news.google.com         
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide...
Google News at Macroaxis
over three months ago at finance.yahoo.com         
ESSA Pharma Insiders Placed Bullish Bets Worth US709.0k
Yahoo News
over three months ago at simplywall.st         
ESSA Pharma Insiders Added US709.0k Of Stock To Their Holdings
Simply Wall St News at Macroaxis
over three months ago at www.macroaxis.com         
Disposition of 50000 shares by Berger Franklin M of ESSA Pharma at 2.67 subject to Rule 16b-3
Macroaxis News
over three months ago at investing.com         
Essa Pharma COO sells shares worth over 4,000
Investing News at Macroaxis
over three months ago at news.google.com         
ESSA Pharma Stock Price Passes Above 50-Day Moving Average of 5.52 - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
Trading Signals - Stock Traders Daily
Google News at Macroaxis
over three months ago at finance.yahoo.com         
EPIX Masofaniten Combination Therapy with Enzalutamide Increases rPFS Increasing Valuation to 33 per...
Yahoo News
Far too much social signal, news, headlines, and media speculation about ESSA Pharma that are available to investors today. That information is available publicly through ESSA media outlets and privately through word of mouth or via ESSA internal channels. However, regardless of the origin, that massive amount of ESSA data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ESSA Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ESSA Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ESSA Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ESSA Pharma alpha.

ESSA Pharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Parkinson David Ross of 350000 shares of ESSA Pharma at 9.04 subject to Rule 16b-3
11/27/2024
2
Stockholder Alert Robbins LLP Informs Investors of the ESS Pharma Inc. Class Action - cnhinews.com
01/28/2025
3
Levi Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 EPIX
02/04/2025
4
Levi Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit EPIX
02/10/2025
5
ESSA Pharma Inc. Class Action The Gross Law Firm Reminds ESSA Pharma Inc. ...
02/12/2025
6
Levi Korsinsky Notifies ESSA Pharma Inc. ...
02/13/2025
7
EPIX STOCK NEWS EPIX Shareholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Essa Pharma Inc.
02/14/2025
8
Investors who lost money on ESSA Pharma Inc. ...
02/18/2025
9
Class Action Filed Against ESSA Pharma Inc. Seeking Recovery for Investors Contact The Gross Law Firm
02/20/2025
10
Levi Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ...
02/21/2025

Additional Tools for ESSA Stock Analysis

When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.